Conducted in the early 1990s, this study provided critical evidence on the benefits of statins in reducing cardiovascular events in individuals without a history of CHD.
High low-density lipoprotein (LDL) cholesterol levels are a well-established risk factor for developing CHD.
While previous studies[3][4][5] had demonstrated the benefits of lipid-lowering agents in patients with existing CHD, the WOSCOPS was one of the first large-scale trials to evaluate the efficacy of statins for primary prevention in individuals without a prior history of cardiovascular events.
[8] The WOSCOPS was a pivotal trial that contributed to the broader acceptance and use of statins in the primary prevention of cardiovascular disease.
Its findings have been corroborated by subsequent studies and meta-analyses, reinforcing the role of statins in reducing the risk of CHD in various populations.